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The activation of human platelets by a-thrombin is
mediated at least in part by cleavage of protease-acti-
vated G-protein-coupled receptors, PAR-1 and PAR-4.
Platelet glycoprotein Iba also has a high affinity binding
site for a-thrombin, and this interaction contributes to
platelet activation through a still unknown mechanism.
In the present study the hypothesis that GpIba may
contribute to platelet activation by modulating the hy-
drolysis of PAR-1 on the platelet membrane was inves-
tigated. Gel-filtered platelets from normal individuals
were stimulated by a-thrombin, and the kinetics of
PAR-1 hydrolysis by enzyme was followed with flow cy-
tometry using an anti-PAR-1 monoclonal antibody
(SPAN 12) that recognizes only intact PAR-1 molecules.
This strategy allowed measurement of the apparent
kcat/Km value for thrombin hydrolysis of PAR-1 on intact
platelets, which was equal to 1.5 6 0.1 3 107 M21 sec21.
The hydrolysis rate of PAR-1 by thrombin was measured
under conditions in which thrombin binding to GpIb
was inhibited by different strategies, with the following
results. 1) Elimination of GpIba on platelet membranes
by mocarhagin treatment reduced the kcat/Km value by
about 6-fold. 2) A monoclonal anti-GpIb antibody re-
duced the apparent kcat/Km value by about 5-fold. 3) An
oligonucleotide DNA aptamer, HD22, which binds to the
thrombin heparin-binding site (HBS) and inhibits
thrombin interaction with GpIba, reduced the apparent
kcat/Km value by about 5-fold. 4) Displacement of
a-thrombin from the binding site on GpIb using PPACK-
thrombin reduced the apparent kcat/Km value by about
5-fold, and 5) mutation at the HBS of thrombin (R98A)
caused a 5-fold reduction of the apparent kcat/Km value
of PAR-1 hydrolysis. Altogether these results show that
thrombin interaction with GpIb enhances the specific-
ity of thrombin cleavage of PAR-1 on intact platelets,
suggesting that GpIb may function as a “cofactor” for
PAR-1 activation by thrombin.
Platelet activation by the coagulation protease a-thrombin
plays a crucial role in physiologic hemostatic processes and in
thrombotic diseases. The activation of human platelets by
thrombin is mediated by at least two receptors belonging to the
family of protease-activated receptors (PARs),1 i.e. PAR-1 and
PAR-4 (1–2). These receptors are activated upon cleavage by
thrombin and mediate transmembrane signaling by coupling to
G-proteins (1–2). a-Thrombin also binds with high affinity to
the platelet glycoprotein Ib (GpIb) that belongs to the leucine-
rich repeat family of proteins (3). Thrombin binding to GpIb
contributes to platelet activation by the enzyme, as demon-
strated by the finding that Bernard-Soulier platelets, which
lack the GpIb-IX-V complex, have a delayed response to throm-
bin stimulation (4). In addition, several in vitro studies have
demonstrated that the inhibition of thrombin binding to GpIb
by different strategies causes a reduction in thrombin-induced
platelet activation (5–9).
The mechanism by which the binding of a-thrombin to GpIb
contributes to platelet activation is not clear. Numerous stud-
ies have shown that a proteolytic-active enzyme is required to
activate platelets. PPACK-thrombin, which retains its ability
to bind to GpIb, does not induce platelet aggregation (10).
Moreover, GpIb does not undergo cleavage by thrombin. On the
other hand, the cleavage of G-protein-coupled PARs seems to
be essential in platelet activation and transmembrane signal-
ing. The finding that thrombin binding to GpIb involves a
distinct thrombin domain, the HBS, which is far from the
thrombin catalytic site and the fibrinogen recognition site (7–
9), would suggest that a ternary complex thrombinzGpIbzPAR-1
may form on the platelet membrane that could be responsible
for optimal hydrolysis and signal transduction.
In the present study, the hypothesis that thrombin binding
to GpIb may affect the hydrolysis of PAR-1 by the enzyme on
intact platelets was investigated. The hydrolysis of PAR-1 was
evaluated as a paradigm to construct a model where GpIb acts
as a cofactor for PAR(s) cleavage.
EXPERIMENTAL PROCEDURES
Materials—Human a-thrombin was purified and characterized as
previously reported (11). Mutant thrombin R98A, which contains an
alanine substitution at Arg-98 (thrombin B-chain numbering),2 and
recombinant wild-type (WT) human thrombin were obtained and char-
acterized as described previously (12). The mutant form retains its
catalytic activity, although its ability to interact with heparin was
severely impaired, as demonstrated by in vitro studies on heparin-
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catalyzed thrombin inhibition by anti-thrombin III. PPACK-thrombin
was obtained and characterized as previously reported (13).
Mocarhagin was purified from cobra venom, as described previously
(14), at the Baker Medical Research Institute, Praharan, Australia.
HD22, a single-stranded DNA oligonucleotide with the sequence 59-
AGTCCGTGGTAGGGCAGGTTGGGGTGACT-39, which binds with
high affinity to the heparin binding site of thrombin (15), was a kind gift
of Prof. J. I. Weitz, (McMaster University, Hamilton, Ontario).
The PAR-1-(38–60) peptide, LDPRSFLLRNPNDKYEPFWEDEE,
was synthesized and characterized by mass spectrometry at Primm
s. r. l. (Milan, Italy). The monoclonal antibody LJ1b10, which is able to
selectively inhibit thrombin-GpIb interaction, was a generous gift from
Dr. Zaverio Ruggeri (The Scripps Research Institute, La Jolla, CA).
Preparation of Platelets—Platelets from normal donors were ob-
tained by gel filtration of platelet rich plasma onto Sepharose 2B
columns (25 3 1 cm) equilibrated with a buffer containing 20 mM Hepes,
135 mM NaCl, 5 mM KCl, 5 mM glucose, 0.2% albumin, pH 7.4. EDTA
(1-mM final concentration) was added to PRP prior to gel filtration to
avoid activation during washing procedures. The platelet count was
adjusted to 1 3 105/ml with washing buffer in all the experiments.
GpIb-depleted platelets were prepared by using the cobra venom
metalloproteinase, mocarhagin, which selectively cleaves GpIb between
Glu-282 and Asp-283 residues, according to a previously reported
method (9). Briefly, gel-filtered platelets were incubated with 10 mg/ml
mocarhagin and 1 mM Ca21 for 20 min at 37 °C. The mocarhagin
activity was stopped by 2 mM EDTA. An aliquot of intact platelets (i.e.
not exposed to mocarhagin) from the same donor was subjected to the
same incubation with 1 mM Ca21 for 20 min at 37°, addition of 2 mM
EDTA and was used as a control. Evaluation of GpIb cleavage was
performed by flow cytometry using the fluorescein isothiocyanate
(FITC)-conjugated anti-GpIb monoclonal antibody CD42b (SZ2 clone)
(Immunotech, Marseille, France), whose epitope on GpIba is lost fol-
lowing mocarhagin treatment (5).
Measurement of PAR-1 Hydrolysis by Thrombin on Intact Platelets—
Gel-filtered platelets, intact or GpIb-depleted, were exposed to a-throm-
bin, whose final concentration ranged from 1 nM to 10 nM in different
experiments. At different times (from 15 to 600 s), aliquots of 50 ml of
stimulated platelets were drawn into tubes containing 100 nM hirudin,
which abolished the thrombin activity. The tubes were placed in ice to
stop internalization of cleaved PAR-1 molecules (16).
In different experiments, intact platelets were stimulated by
a-thrombin in the presence of either 130 mg/ml anti-GpIb SZ2 mAb, 400
nM HD22 aptamer, or 140 nM PPACK-thrombin.
In the experiments using the R98A thrombin mutant and the recom-
binant WT human thrombin, gel-filtered platelets were stimulated by
the enzymes at a concentration of 1 nM.
The presence of intact PAR-1 molecules on the platelet membrane at
different times after thrombin stimulation was measured by using a
phycoerythrin (PE)-conjugated anti-PAR-1 mAb, SPAN12 clone (Immu-
notech). SPAN12 recognizes the NH2-terminal peptide of PAR-1 resi-
dues 35–46 (NATLDPR2SFLLR), where “2” indicates the cleavage
site by thrombin. This mAb reacts only with uncleaved PAR-1 molecules
(16). In preliminary experiments, PE-SPAN12 was added to 1 3 106
platelets at increasing amounts (0.5, 1, 1.5, 2, 2.5, and 3 mg) for 30 min
at 4 °C. Platelet suspensions were subsequently washed in phosphate-
buffered saline/EDTA at 1500 rpm for 5 min. An optimal resolution of
control and test histograms was obtained with 2 mg of anti-PAR-1
mAb/1 3 106 platelets. Thus, this saturating dose was chosen for
subsequent experiments. Background fluorescence was determined us-
ing a PE-conjugated isotype-matched irrelevant mAb.
At the end of stimulation by thrombin, 2 mg of SPAN-12 was added
to each tube containing platelets and hirudin. After incubation at 4 °C
for 30 min, platelets were washed in phosphate-buffered saline/EDTA,
and samples were run through a FACScan flow cytometer (Becton
Dickinson, Mountain View, CA) equipped with an argon laser emitting
at 488 nm. PE signals were collected and recorded at 575 nm; gain
setting stability was verified daily with Calibrite BeadsTM® (Becton
Dickenson). A minimum of 20,000 events were acquired in list mode
using CellQuestTM software (Becton Dickenson); forward (FSC) and
side (SSC) scatter were collected with logarithmic amplification, and
fluorescent emissions were collected on a 4-decade logarithmic scale.
Levels of silver expression were measured in terms of the geometric
mean of specific fluorescence.
Measurement of PAR-1-(38–60) Peptide Hydrolysis by WT Thrombin
and R98A Thrombin—Hydrolysis of the PAR-1-(38–60) peptide by
thrombin was followed by measuring the release of the peptide LDPR,
resulting from the cleavage of the NH2 terminus of PAR-1, according to
a previously described method (7). Briefly, 0.5 mM PAR-1-(38–60) pep-
tide was incubated with 0.1 nM WT thrombin or 0.1 nM R98A thrombin
in HEPES (10 mM), NaCl (0.15 M), polyethylene glycol Mr 6000 (0.1%)
pH 7.5 at 25°. At time intervals (1, 2, 3, 4, 8, 12, and 15 min) the reaction
was stopped with 0.3 M HClO4, and the cleaved peptide was measured
by reversed-phase HPLC, using a 250 3 4.6 mm RP-304 column
(Bio-Rad).
Experimental concentrations of PAR-1-(38–60) peptide cleaved at
time t (Pt), were fitted to the following equation,
Pt 5 P‘~1 2 exp~2kobst!! (Eq. 1)
where P‘ is the peptide concentration at t 5 ‘ and kobs is the pseudo
first-order rate of PAR-1 hydrolysis, equal to e0 3 kcat/Km (e0 is the
thrombin concentration).
Aggregometry Studies—Gel-filtered platelets were suspended in
HEPES buffer, as detailed above, containing 2 mM CaCl2 and used at a
final count of 200,000/ml. Platelet aggregation by thrombin was studied
using a 4-channel PACKS-4 aggregometer (Helena Laboratories, Sun-
derland, UK), according to the Born method. In some experiments,
platelets were stimulated by recombinant human WT thrombin and
R98A thrombin at concentrations ranging from 0.39 nM to 50 nM. In
other experiments, platelets were stimulated by WT thrombin at con-
centrations ranging from 0.625 to 20 nM, or by R98A thrombin at
concentrations ranging from 3.125 to 100 nM, in the absence and in the
presence of monoclonal antibody LJIb10 (0.15 mg/ml, final concentra-
tion). The velocity of absorbance change was measured and expressed
as percent/min.
RESULTS
Measurement of Thrombin Hydrolysis of PAR-1 on Intact
Platelets—Measurement of PAR-1 hydrolysis by a-thrombin
was accomplished by a cytofluorimetric method, using a fluo-
rescent monoclonal antibody, SPAN-12, that recognizes only
the intact NH2-terminal portion of the receptor. After cleavage,
the mAb does not interact with the receptor, so that disappear-
ance of the mAb signal reflects the hydrolytic reaction. Inter-
nalization of the receptor, which could also lead to loss of
signal, has been shown to occur only for cleaved PAR-1 mole-
cules (16–18). Under the conditions of the study, using intact
gel-filtered platelets, the concentration of PAR-1 present on the
platelet membrane (100–2000 copies of PAR-1/platelet, Refs.
19–20) is much lower (nanomolar) than the Km value of its
hydrolysis by thrombin (micromolar range), so that the kinetics
of PAR-1 cleavage can be fitted to an exponential equation,
whose rate constant, kobs, is proportional to the kcat/Km value
of thrombin-PAR-1 hydrolysis, according to the following
equation (21).
kobs 5 e0kcat/Km (Eq. 2)
In the experimental setup, the fluorescent signal given by
the SPAN-12 mAb was monitored as a function of time at fixed
thrombin concentrations. Although the antibody staining pro-
cedure is relatively long compared with PAR-1 cleavage kinet-
ics at the concentrations of thrombin used, this limitation was
overcome by performing the staining on ice and using high
concentrations of hirudin to completetly inhibit thrombin ac-
tivity. Fluorescence signals measured as a function of time
were fitted to the following equation,
Flt 5 Fl0exp~2kobst! 1 Fl‘ (Eq. 3)
where Flt is the fluorescence at time t, Fl0 is the initial, Fl‘ is
the final fluorescence value, and kobs is the observed rate con-
stant for the single exponential decay. Knowing the enzyme
concentration and using Eq. 2, the kcat/Km value could be cal-
culated. Additional experiments were carried out to confirm the
validity of this experimental approach. From Eq. 2 it follows
that if the kobs value actually reflects the kcat/Km value of the
hydrolytic reaction, then it must depend on the enzyme
concentration.
Thus, the observed rate constant was measured at different
thrombin concentrations, ranging from 0.5 to 8 nM. The above
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analysis assumes that the concentration of the uncleaved re-
ceptor does not change during the time course of the experi-
ments. To test this hypothesis, control experiments were car-
ried out with a different mAb, WEDE-15, directed against the
COOH-terminal domain of the PAR-1 cleavage site. Using
thrombin in the nanomolar range, only a decrease in WEDE-15
binding to gel-filtered platelets was observed, consistent with
an internalization process of the hydrolyzed PAR-1 receptor,
which has been previously reported (16–18). This implies that
over the time course of the experiments, newly exposed recep-
tors (present in the surface connecting system) did not signif-
icantly alter the total PAR-1 concentration and that loss of
WEDE-15 binding to platelets is likely because of an internal-
ization process involving the cleaved receptor molecules. These
findings therefore allow calculation of the apparent kcat/Km
value pertaining to thrombin-PAR-1 interaction as outlined
above.
As shown in Fig. 1, the pseudo first-order rate constant of
PAR-1 cleavage increased as a function of a-thrombin concen-
tration ranging from 0.5 to 8 nM, consistent with the canonical
Michaelis scheme for serine protease activity that predicts a
linear relation between the catalytic rate and the enzyme con-
centration (Eq. 2). The inset in Fig. 1 demonstrates this rela-
tionship with the slope of the straight line expressing the
apparent kcat/Km value, which is equal to 1.5 6 0.1 3 10
7 M21
sec21. This value is similar to that for thrombin hydrolysis of
the PAR-1-(38–60) peptide in solution (see below), supporting
the validity of the cytofluorimetric strategy used in this
investigation.
Effect of Inhibiting Thrombin-GpIb Interaction on Hydrolysis
of PAR-1 in Intact Platelets—The effect of inhibiting thrombin-
GpIb interaction on the enzyme hydrolysis rate of PAR-1 was
evaluated by five different experimental strategies: 1) elimina-
tion of the thrombin binding site on GpIba by mocarhagin
treatment of gel-filtered platelets, 2) use of a monoclonal anti-
body SZ2, which binds to GpIba and inhibits thrombin inter-
action, 3) use of the DNA aptamer HD22, which specifically
interacts with the heparin binding site (HBS) of thrombin and
inhibits enzyme binding to GpIba, 4) use of a thrombin mutant,
R98A, which bears a perturbation of the HBS structure, and 5)
use of PPACK-thrombin in competition experiments with
a-thrombin.
The removal of the NH2-terminal 1–282 region of GpIba by
mocarhagin severely impaired the PAR-1 hydrolysis by throm-
bin. As shown in Fig. 2, the kobs value for PAR-1 hydrolysis by
1 nM a-thrombin was reduced by about 6-fold in GpIb-depleted
platelets compared with untreated platelets. The inset in Fig. 2
shows that the kcat/Km value of PAR-1 hydrolysis in mocarha-
gin-treated platelets, which was 2.8 6 0.3 3 106 M21 sec21,
decreased 5.4-fold in comparison with untreated platelets. Sim-
ilar results were obtained by using two different competitive
inhibitors of thrombin binding to GpIb, the mAb SZ2, which
interacts with the thrombin binding site on GpIba (5, 22), and
the DNA aptamer HD22, which interacts with the thrombin
HBS. Fig. 3 clearly shows that in both cases a roughly 5–6-fold
reduction in kobs was obtained using a large excess of the
inhibitors. Although the targets of the inhibitors were differ-
ent, the effect was the same, as in both cases the thrombin-
GpIb interaction was inhibited. Altogether these results show
that inhibition of thrombin binding to GpIba causes a marked
reduction of the apparent catalytic specificity constant of the
thrombin-PAR-1 interaction.
The findings reported above raise the question of whether
thrombin interaction with GpIba might induce an intracellular
FIG. 1. Kinetics of PAR-1 cleavage by different thrombin con-
centrations, measured as a loss of SPAN12 mAb fluorescence
over time. The experimental conditions reported under “Experimental
Procedures” included 60,000 gel-filtered platelets/ml and 0.12 mg/ml of
the mAb. Solid lines are drawn according to Eq. 3 with the bestfit kobs
values: (E), 6.6 6 0.6 3 1023 sec21; ( l ), 1.2 6 0.3 3 1022 sec21; (M),
2.9 6 0.6 3 1022 sec21; (L), 3.7 6 0.4 3 1022 sec21; (), 1.2 6 0.3 3 1021
sec21. Data are presented as mean 6 S.E. from two different determi-
nations. In the inset, the experimental values of kobs pertaining to
PAR-1 cleavage on intact platelets are plotted as a function of thrombin
concentration, according to Eq. 2. The straight line was drawn accord-
ing to the bestfit kcat/Km value of 1.5 6 0.1 3 10
7 M21 sec21.
FIG. 2. Measurement of the kobs value pertaining to PAR-1
hydrolysis on intact and mocarhagin-treated platelets. Experi-
mental conditions were similar to those reported in the legend to Fig. 1.
Intact (E) and mocarhagin-treated ( l ) (10 mg for 10 min at 37 °C)
platelets were exposed to 1 nM a-thrombin, and the cleaved PAR-1 was
estimated cytofluorimetrically by the SPAN 12 mAb, as described under
“Experimental Procedures.” The solid lines were drawn by nonlinear
regression according to Eq. 3, with the bestfit kobs values: (E), 1.8 6
0.3 3 1022 sec21; (l ), 0.3 6 0.07 3 1022 sec21. Data are presented as
mean 6 S.E. from two different determinations. In the inset, the exper-
imental values of kobs pertaining to PAR-1 cleavage on mocarhagin-
treated (l ) and, for comparison, intact platelets (E) are plotted as a
function of thrombin concentration, according to Eq. 2. The straight
lines were drawn according to the bestfit kcat/Km value: (E), 1.5 6 0.1 3
107 M21 sec21; ( l ), 2.8 6 0.3 3 106 M21 sec21.
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signal that could alter the interaction of thrombin with PAR-1,
for instance through liberation of a second messenger molecule
acting on the expression/conformation of PAR-1 molecules.
PPACK-thrombin, which is catalytically inactive, yet still able
to interact with GpIb, did not cause aggregation of gel-filtered
platelets, even at 200 nM and did not induce any intracytoplas-
mic Ca21 flux (data not shown), in accordance with numerous
previous reports (6, 10). On the other hand, competition exper-
iments showed that a high concentration of PPACK-thrombin
(140 nM), by displacing a-thrombin from GpIba, reduced by
about 3-fold the apparent kcat/Km value of PAR-1 hydrolysis on
intact platelets, as shown in Fig. 4. Again, this experiment is in
accord with the other functional experiments described above
and corroborates the hypothesis that thrombin-GpIb interac-
tion is able to enhance the specificity of thrombin cleavage of
PAR-1 on intact platelets.
This hypothesis was further supported by the finding that a
thrombin mutant, R98A, bearing an alanine substitution in the
HBS of thrombin at Arg-98, showed a similar reduction of the
kobs value of PAR-1 hydrolysis compared with recombinant WT
human thrombin, as shown in Fig. 5. In control experiments,
this diminished activity of PAR-1 hydrolysis on platelets could
not be attributed to an intrinsic reduction of the catalytic
efficiency of the thrombin mutant. Solution experiments em-
ploying the PAR-1-(38–60) peptide, bearing both the cleavage
and the recognition site for thrombin (23), demonstrated that
thrombin R98A cleaved the solution peptide with a kcat/Km that
was slightly higher than that of WT thrombin, as shown in Fig.
6. This finding is consistent with the hypothesis that the re-
duction of the kcat/Km value of PAR-1 hydrolysis on intact
platelets is likely because of a defective interaction of the
thrombin mutant with GpIba. Moreover, the biological effect of
this mutation on platelet activation can be seen in Fig. 7, which
shows that the EC50 value for platelet aggregation by R98A is
roughly 10-fold higher compared with WT thrombin.
Effect of Anti-GpIb mAb LJIb10 on Platelet Aggregation by
WT Thrombin and R98A Mutant Thrombin—These experi-
ments were carried out to evaluate whether the thrombin HBS
could be involved in the interaction with other thrombin recep-
tors. PAR-1 was already demonstrated not to be involved in
HBS ligation (6–9), but PAR-4 could potentially contain a
binding site for the thrombin HBS, although a close inspection
of the PAR-4 primary sequence (24) does not show a negatively
charged domain to support this hypothesis. The mAb LJ1b10
specifically inhibits the interaction of thrombin with GpIba,
without affecting the binding of von Willebrand factor to GpIba
(22, 25). The use of this mAb allows one to rule out a potential
inhibitory effect on the aggregation of gel-filtered platelets that
could be attributed to an impaired interaction of GpIb with
platelet von Willebrand factor, which is released upon throm-
bin stimulation.
As shown by Fig. 8A, platelets stimulated by WT thrombin
had a rightward shift in the aggregometric dose-response curve
in the presence of 0.15 mg/ml LJIb10 (with EC50 values of
4.43 6 0.4 nM and 10.15 6 0.77 nM, respectively). This finding
is in agreement with the hypothesis that specific inhibition of
thrombin binding to GpIb causes a reduced platelet response to
the agonist. In contrast, the dose-response curve obtained by
stimulating platelets with thrombin mutated at the HBS (Fig.
8B) was not affected at all by the presence of the mAb (with
EC50 values of 23.5 6 2.8 nM and 22.1 6 5 nM, respectively).
This result is in agreement with the concept that the thrombin-
GpIb interaction involves the enzyme HBS, as the LJ-Ib10 mAb
could not induce any inhibition of the R98A thrombin-induced
platelet activation. This result would also suggest that the
FIG. 3. Measurement of the kobs value pertaining to PAR-1
hydrolysis in the presence of inhibitors of thrombin-GpIb inter-
action. Quantification of PAR-1 hydrolysis was accomplished as re-
ported in the legend to Fig. 1, using 2 nM a-thrombin, but in the
presence of 400 nM HD22 aptamer (l )or 130 mg/ml anti-GpIb SZ2 mAb
(M), both inhibiting the thrombin-GpIb interaction. The kinetics of
PAR-1 hydrolysis in the absence of any inhibitor, but in the presence of
130 mg/ml human IgG used as control, is reported as well (E). Data are
presented as mean 6 S.E. from two different determinations. The lines
were drawn by nonlinear regression according to Eq. 3, with the bestfit
kobs values: (E), 3.2 6 0.6 3 10
22 sec21 (solid line); (l ), 0.48 6 0.06 3
1022 sec21 (dashed line); (M), 0.6 6 0.09 3 1022 sec21 (dotted line).
FIG. 4. Effect of displacement of a-thrombin binding to GpIb
by high PPACK-thrombin concentration on PAR-1 hydrolysis.
Kinetics of PAR-1 hydrolysis, as described in the legend to Fig. 1, using
1 nM a-thrombin, in the absence (E) or presence (l ) of 140 nM PPACK-
thrombin. Data are presented as mean 6 S.E. from two different de-
terminations. Solid lines were drawn by nonlinear fitting according to
Eq. 3, with the bestfit kobs values: (E), 1.6 6 0.4 3 10
22 sec21. (l ), 0.6 6
0.08 3 1022 sec21.
FIG. 5. Measurement of the kobs value pertaining to PAR-1
hydrolysis by wild-type and the R98A thrombin mutant. Kinetics
of PAR-1 cleavage by wild-type (E) and the R98A thrombin (l ) at 1 nM
concentration. Gel-filtered platelets were used at a concentration of
60,000/ml. Data are presented as mean 6 S.E. from two different de-
terminations. The solid lines were drawn by nonlinear regression ac-
cording to Eq. 3, with the bestfit kobs values: (E), 1.9 6 0.2 3 10
22 sec21,
(l ), 0.34 6 0.05 3 1022 sec21.
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thrombin HBS is involved only in GpIb binding and not in the
interaction with other platelet receptors, such as PAR-4.
DISCUSSION
In this study, the role of GpIba in the hydrolysis of PAR-1 by
thrombin and in thrombin-induced platelet activation was ex-
amined. GpIba binds thrombin with high affinity and contrib-
utes to platelet activation by the enzyme; however, there is no
evidence that thrombin ligation to GpIb per se is able to trigger
platelet activation. Results from the present study show that
GpIba can function as a cofactor for PAR-1 cleavage and acti-
vation in human platelets. In fact, by directly measuring the
hydrolysis of PAR-1 on intact platelets, it was possible to eval-
uate the effect of the inhibition of thrombin binding to GpIba on
PAR-1 cleavage. The cytofluorimetric strategy used to detect
PAR-1 hydrolysis on platelets allowed measurement of the
apparent specificity constant, kcat/Km, pertaining to thrombin
hydrolysis of the receptor. It is noteworthy that the value
measured in intact cells is similar to that for hydrolysis of the
PAR-1-(38–60) peptide in solution, as confirmation of the va-
lidity of the experimental method. Interestingly, the inhibition
of thrombin interaction with GpIb on platelets, obtained by
different experimental strategies, consistently showed a 5- to
6-fold reduction of the specificity rate constant of PAR-1 hy-
drolysis by thrombin. This finding might suggest that in the
absence of GpIb on the platelet membrane, the thrombin-
PAR-1 interaction is partially hampered or less productive,
given that the kcat/Km value is much lower than that measured
with the PAR-1-(38–60) peptide in solution.
Thrombin bound to GpIba via its HBS, whose blockade
caused a reduction in both PAR-1 hydrolysis and platelet ag-
gregation. That the HBS is not directly involved in the inter-
action with PAR-1 was demonstrated by the experiment show-
ing that the HBS mutant thrombin, R98A, cleaves the PAR-1-
(38–60) peptide in solution with an apparent kcat/Km similar to
or even higher than that pertaining to WT thrombin. Platelet
aggregation by R98A thrombin was not sensitive to the pres-
ence of the anti-GpIb mAb LJ-Ib10, whereas the aggregation by
WT thrombin showed a rightward-shift of the dose-response
curve (Fig. 8). In the former case, in fact, thrombin binding to
GpIb was already impaired by HBS perturbation, whereas in
the latter case use of the mAb blocked the GpIb contribution to
platelet aggregation. The effect of the anti-GpIb mAb on the
aggregation by WT thrombin is in agreement with the inhibi-
tory effect of the mAb on PAR-1 activation by thrombin via the
inhibition of enzyme binding to GpIb.
Because inhibition of the thrombin-GpIb interaction, ob-
tained through different methods, caused in all cases a reduc-
tion of the PAR-1 hydrolysis rate, this finding was interpreted
as a consequence to a positive linkage between thrombin bind-
ing to GpIb and the catalytic interaction of this enzyme com-
FIG. 6. Measurement of the kcat/Km value pertaining to the
PAR-1-(38–60) peptide hydrolysis by wild-type and the R98A
thrombin mutant. Hydrolysis of the PAR-1-(38–60) peptide was
measured by the HPLC method, using 0.1 nM wild-type (l ) and R98A
thrombin mutant () and 0.5 mM peptide. The experimental points are
the mean of two determinations. Solid lines were drawn by nonlinear
regression according to Eq. 1, with the bestfit kobs values: (l ), 4.3 6
0.3 3 107 M21 sec21, (), 7 6 0.8 3 107 M21 sec221.
FIG. 7. Platelet aggregation capacity of the wild-type and the
R98A thrombin mutant. Gel-filtered platelets used at 200,000/ml
were exposed to different concentrations of wild-type (l ) or R98A
thrombin mutant (E). Data are presented as mean 6 S.E. from two
different determinations. The solid lines were drawn by nonlinear re-
gression with the bestfit EC50 values equal to 1.1 6 0.2 and 10 6 2 nM
for the wild-type and the R98A thrombin mutant, respectively.
FIG. 8. Effect of the anti-GpIb mAb LJIb10 on platelet aggre-
gation by WT and R98A mutant thrombin. Aggregation of gel-
filtered platelets induced by WT thrombin (A) and the R98A thrombin
mutant (B) was measured in the absence ( l ) and presence (E) of the
LJ-Ib10 mAb, as described under “Experimental Procedures.” Data are
presented as mean 6 S.E. from two different determinations. Solid
lines were drawn using the bestfit EC50 values: 4.43 6 0.4 nM and
10.15 6 0.77 nM for WT-thrombin (in the absence and in the presence of
0.15 mg/ml LJ-Ib10, respectively); 23.5 6 2.8 nM and 22.1 6 5 nM for the
R98A mutant (in the absence and in the presence of 0.15 mg/ml LJ-
Ib10, respectively).
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plex with PAR-1. It was previously shown that GpIba in solu-
tion does not alter the kinetic constants of hydrolysis of the
PAR-1-(38–60) peptide (7, 26). This implies that membrane
phenomena are responsible for the effect observed using intact
platelets.
One possible mechanism of action of GpIb could be that this
transmembrane glycoprotein mediates a signal transduction
event that could modify the membrane and/or PAR-1-folding,
so that PAR-1 would be more activatable by thrombin. How-
ever, experiments with PPACK-thrombin did not confirm this
hypothesis. In fact, intraplatelet Ca21 flux was not observed
using PPACK-thrombin that binds to GpIb but does not cleave
PAR-1 (data not shown). Moreover, when PPACK-thrombin
was used along with a-thrombin, it caused, as shown in Fig. 4,
a 3-fold reduction of the apparent kcat/Km value pertaining to
PAR-1 cleavage, in agreement with the effect of the other
inhibitors of thrombin-GpIb binding. PPACK-thrombin would
have caused an enhancement of PAR-1 cleavage, if a positive
intracellular signal were generated. It is postulated that von
Willebrand factor binding to GpIb induces signal transduction
(27), whereas this phenomenon has not yet been demonstrated
for thrombin binding to GpIb. Accordingly, very recent findings
have indicated that thrombin-GpIb interaction is a necessary
but not sufficient condition to induce a procoagulant capacity in
the platelet membrane (28). In addition to thrombin binding to
GpIb, the procoagulant platelet activity has been demonstrated
to arise from both the involvement of the GpIIb-IIIa complex
and the platelet-platelet interaction as well (28).
It may be hypothesized that GpIb would enhance the pro-
ductive collisions between the enzyme and the substrate,
PAR-1, on the membrane surface, essentially acting as a cata-
lyst for the reaction. This hypothesis hinges on the structural
properties of the components involved in the interaction. The
formation of a ternary thrombinzGpIbzPAR-1 complex can be
hypothesized, as GpIb binds to the thrombin HBS, whereas
PAR-1 interacts with both the exosite referred to as fibrinogen
recognition site and the catalytic pocket (6, 9, 23). The positive
effect of GpIb interaction with thrombin might be considered as
a template function, which could enhance the number of pro-
ductive collisions between the enzyme and the PAR-1 sub-
strate. The mechanisms through which this effect takes place is
not in the realm of this study. Further studies are needed to
demonstrate experimentally the formation of the ternary
thrombinzGpIbzPAR-1 complex, as well as to unravel some
structural issues pertaining to the components of this complex.
GpIb is in fact an elongated molecule with a longitudinal axis
of ;550 Å (29). Because the thrombin binding site on GpIba
and the NH2-terminal PAR-1 domain are expected to be located
at roughly 300 and 65–70 Å from the membrane surface, re-
spectively, it has to be demonstrated how a ternary
thrombinzGpIbzPAR-1 adduct could form on the platelet
membrane.
From a physical standpoint, one can reasonably assume that
the kinetics of thrombin binding to GpIb is faster than kinetics
of formation of the thrombinzPAR-1 Michaelis adduct. Thus,
although the association rate constants of thrombinzGpIb and
thrombinzPAR-1 may be similar, the concentration of GpIb is at
least 1–2 orders of magnitude higher than that of PAR-1 on the
platelet membrane (19–20), and thus the bimolecular interac-
tion of thrombin with GpIb is faster than the formation of the
thrombinzPAR-1 adduct. Hence GpIb may function as a cofactor
for PAR-1 activation by thrombin in situ. It is not clear from
this investigation whether this cofactor activity is exclusively
mediated by GpIb alone, or through more complex interactions
involving the entire glycoprotein adduct, GpIb-IX-V. GpV in
fact is known to be cleaved by thrombin, but its role in platelet
activation remains unknown (30).
The cofactorial function of GpIb would resemble the one
recently identified for thrombin interaction with PAR-3 and
PAR-4 on mouse platelets (31). Similarly to GpIb for human
platelets, PAR-3 in mouse platelets does not mediate trans-
membrane signaling, but its loss inhibits the mouse platelet
activation by low thrombin concentrations. The model for
PAR-3 function predicts that this receptor binds thrombin that
remains available on platelet membrane to cleave and activate
nearby PAR-4 molecules. Although PAR-3 and GpIb are com-
pletely different molecules, they might share a cofactorial func-
tion for PARs activation. This model may be of interest for
human platelets, because it introduces the concept that cofac-
tors for PARs activation might regulate the specificity of re-
sponse to proteases of target cells. Regulation of cofactor func-
tion, rather than that of the receptor itself, might thus become
crucial in modulating the effects of proteases on cells. This
concept seems particularly to fit for proteins and enzymes that
do not bear phospholipid binding sites. Membrane surface is
one of the most relevant cofactors usually involved in strongly
accelerating coagulation reactions (32). Many coagulation fac-
tors, such as Factor V, and Factor VIII, operating on a mem-
brane surface, bear specific phospholipid binding sites. The
interaction of thrombin with its PAR-1 substrate, inserted in
the platelet membrane, could be hampered by the lack in the
thrombin molecule of a domain capable of binding to membrane
phospholipids. The high affinity interaction of thrombin with
GpIb could overcome this limitation. The thrombin-GpIb inter-
action could pay the energetic cost to favor an otherwise ham-
pered interaction between the enzyme and its macromolecular
substrate. Likewise, an interesting model for this kind of co-
factorial function of protease receptors is that recently de-
scribed for the endothelial Protein C receptor involved in acti-
vating Protein C along with the thrombinzthrombomodulin
complex on the surface of endothelial cells (33).
At this point one might question whether the 5–6-fold in-
crease of the kcat/Km value of PAR-1 hydrolysis caused by
thrombin interaction with GpIb could be of physiological rele-
vance. The present data cannot indicate whether the increase
of the kcat/Km value arises from either an increase of kcat, or a
decrease of Km value, or else a combination of both phenomena.
The present study shows that, under physiological conditions,
thrombin cleaves PAR-1 according to a pseudo first-order ki-
netics. Under this condition, whatever the mechanism, an in-
crease of 5–6-fold of the kcat/Km value of PAR-1 hydrolysis leads
to a 5–6-fold increase of the net velocity of its cleavage, accord-
ing to Eq. 2. Although the GpIb effect on PAR-1 activation is
not dramatic, if compared with other similar phenomena of the
blood coagulation system (33), it could likely be physiologically
relevant. In fact, the PAR-1 shut-off is a very rapid process
after cell activation by thrombin (34), and thus a very efficient
enzyme interaction with PAR-1 molecules is needed to generate
an optimal amount of activated receptors required for a full cell
activation.
The results from the present and previous studies show that
a-thrombin binding to GpIba has a net prohemostatic effect, as
not only is this interaction able to enhance the hydrolysis of
PAR-1 on the platelet membrane, but also protects the enzyme
from the heparin-catalyzed inhibition by anti-thrombin III (9).
The demonstration that the specific inhibition of thrombin-
GpIb interaction leads to reduced thrombin cleavage of PAR-1
on intact platelets, might open the way to new strategies for
specific modulation of platelet responses to thrombin stimula-
tion in different clinical settings.
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